At the time of writing, Mural Oncology plc [MURA] stock is trading at $1.66, up 7.10%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MURA shares have lost -6.74% over the last week, with a monthly amount drifted -34.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mural Oncology plc [NASDAQ: MURA] stock has seen the most recent analyst activity on March 25, 2025, when Raymond James downgraded its rating to a Outperform but kept the price target unchanged to $18 for it. Previously, Morgan Stanley downgraded its rating to Equal-Weight on March 25, 2025. On June 28, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $15 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $13 on April 04, 2024.
For the past year, the stock price of Mural Oncology plc fluctuated between $0.95 and $4.74. Mural Oncology plc [NASDAQ: MURA] shares were valued at $1.66 at the most recent close of the market.
Analyzing the MURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -38.86%, Pretax Profit Margin comes in at -42.14%, and Net Profit Margin reading is -42.14%. To continue investigating profitability, this company’s Return on Assets is posted at -1.68, Equity is -1.22 and Total Capital is -2.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5535 points at the first support level, and at 1.4471 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.7629, and for the 2nd resistance point, it is at 1.8659.
Ratios To Look Out For
It is important to note that Mural Oncology plc [NASDAQ:MURA] has a current ratio of 2.87. In addition, the Quick Ratio stands at 2.87 and the Cash Ratio stands at 2.71.
Transactions by insiders
Recent insider trading involved Keson-Brookes Maiken, that happened on Jul 22 ’25 when 2572.0 shares were sold. Keson-Brookes Maiken completed a deal on Jul 18 ’25 to sell 2158.0 shares. Meanwhile, CLO Maiken Keson-Brookes bought 2572.0 shares on Jul 22 ’25.
